Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00416728
Status:
COMPLETED
Last Update Posted:
2007-06-22
First Post:
2006-12-27
Brief Title:
Bioavailability of Aliskiren and Valsartan as a Single Tablet vs the Same Doses of the Two Drugs Given Separately to Healthy Subjects
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
An Open-Label Randomized Two-Treatment Two Period Crossover Single-Dose Study to Determine the Relative Bioavailability of Fixed Combination of Final Market Image FMI AliskirenValsartan 15080 mg Tablets and the Free Combination of Aliskiren 150 mg and Valsartan 80 mg in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2007-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the bioavailability of aliskiren and valsartan as a single tablet compared to the same doses of the two drugs given as two separate tablets in healthy subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None